uniQure N.V. Operating Costs and Expenses
uniQure N.V. (QURE) reported Operating Costs and Expenses of $289.45 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingCostsAndExpenses · last filed 2024-02-28
- uniQure N.V. operating costs and expenses for fiscal 2023 was $289.45M, a 14.57% increase from fiscal 2022.
- uniQure N.V. operating costs and expenses for fiscal 2022 was $252.65M, a 26.43% increase from fiscal 2021.
- uniQure N.V. operating costs and expenses for fiscal 2021 was $199.84M, a 21.13% increase from fiscal 2020.
- uniQure N.V. operating costs and expenses for fiscal 2020 was $164.98M, a 28.61% increase from fiscal 2019.
| Period end | Operating Costs and Expenses 12 month |
|---|---|
| 2023-12-31 | $289.45M 10-K · filed 2024-02-28 |
| 2022-12-31 | $252.65M 10-K · filed 2024-02-28 |
| 2021-12-31 | $199.84M 10-K · filed 2024-02-28 |
| 2020-12-31 | $164.98M 10-K · filed 2023-02-27 |
| 2019-12-31 | $128.28M 10-K · filed 2022-02-25 |
| 2018-12-31 | $100.11M 10-K · filed 2021-03-01 |
| 2017-12-31 | $96.81M 10-K · filed 2020-03-02 |
| 2016-12-31 | $98.51M 10-K · filed 2019-02-28 |
| 2015-12-31 | $82.51M 10-K · filed 2018-03-14 |
| 2014-12-31 | $60.84M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |